Related Experiment Videos
Autologous stem cell transplantation for multiple myeloma: a single centre experience
Advances in Clinical Pathology : the Official Journal of Adriatic Society of Pathology
|June 8, 1999
Summary
Autologous transplantation using peripheral blood stem cells (PBSC) is effective for multiple myeloma (MM). Newly diagnosed patients showed significantly better outcomes than pretreated patients, indicating a survival benefit for autografted MM patients.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Autologous stem cell transplantation is a key treatment modality for MM.
- Patient characteristics and prior treatment influence transplant outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of autologous stem cell transplantation in MM patients.
- To compare outcomes between newly diagnosed and pretreated MM patients undergoing autograft.
- To assess the survival benefit of autografting compared to conventional therapy.
Main Methods:
- Retrospective analysis of 32 MM patients undergoing autologous transplantation over 3 years.
- Peripheral blood stem cells (PBSC) collected after cyclophosphamide/G-CSF or G-CSF alone.
- Conditioning regimen: busulfan plus melphalan; PBSC reinfusion.
Main Results:
- Overall response rate of 77% (6% complete, 58% partial) in 31 evaluable patients.
- Significant difference in outcomes between newly diagnosed (better) and pretreated patients (p=0.003).
- Median follow-up of 9 months; 3 relapses observed. Significant survival benefit compared to historical controls (p=0.02).
Conclusions:
- Autologous stem cell transplantation is an effective treatment for multiple myeloma.
- Newly diagnosed patients achieve superior outcomes compared to pretreated patients.
- Autografting offers a significant survival advantage for MM patients.